Journal of Cancer Research and Clinical Oncology

, Volume 120, Issue 10, pp 593–598 | Cite as

Reduced oxygenation in a rat mammary carcinoma after chemo- or radiation therapy and reoxygenation with perflubron emulsion/carbogen breathing

  • Beverly A. Teicher
  • Enrique Alvarez Sotomayor
  • Norman P. Dupuis
  • Tetsuya Kusumoto
  • Krishna Menon
Original Papers Experimental Oncology

Abstract

Rat 13672 mammary carcinoma tumors were grown subcutaneously in the hind legs of female Fischer 344 rats to a volume of about 1 cm3. Tumor oxygenation was measured using an EppendorfPO2 histograph. Tumor oxygen measurements were made under four conditions: (a) normal air breathing, (b) carbogen breathing, (c) after intravenous administration of a perflubron emulsion (8 ml/kg) with air breathing and (d) after intravenous administration of a perflubron emulsion (8 ml/kg) with carbogen breathing. Tumor oxygenation was examined without treatment or 24 h and 48 h after treatment with cyclophosphamide (300 mg/kg, i.p.) or cisplatin (8 mg/kg, i.p.] or after the fifth dose of a daily regimen of 3-Gy irradiation (5×3 Gy). Under normal air-breathing conditions 49% of the tumor had aPO2≤670 Pa (5 mm Hg). The degree of hypoxia in the tumors increased after each treatment such that 24 h after treatment 65%–85% of the oxygen readings were ≤670 Pa and 48 h after treatment 60%–74% of the oxygen readings were ≤670 Pa. Administration of the perflubron emulsion/carbogen atmosphere increased the oxygen content of the tumors both without treatment and after each of the treatments. A knowledge of tumor oxygen content over the course of treatment and the ability to increase tumor oxygen should allow for the development of more rational treatment combinations and better treatment outcomes.

Key words

Post-chemotherapy reoxygenation Post-radiation therapy oxygenation Perflubron emulsion/carbogen breathing 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Dorie MJ, Kallman RF (1986) Reoxygenation of the RIF-1 tumor after fractionated radiotherapy. Int J Radiat Oncol Biol Phys 12:1853–1859Google Scholar
  2. Evans RG, Kimler BF, Morantz RA, Vats TS, Gemer LS, Liston V, Lowe N (1990) A phase I/II study of the use of Fluosol as an adjuvant to radiation therapy in the treatment of primary high-grade brain tumors. Int J Radiat Oncol Biol Phys 19:415–420Google Scholar
  3. Evans RG, Kimler BF, Morantz RA, Batnitzky S (1993) Lack of complications in long-term survivors after treatment with Fluosol and oxygen as an adjuvant to radiation therapy for high-grade brain tumors. Int J Radiat Oncol Biol Phys 26:649–652Google Scholar
  4. Garewal H, Skarin A, Kessler J, Smith R, Hedberg J (1989) Fluosol/oxygen in combination with cyclophosphamide in advanced non-small cell lung carcinoma (NSCLC): Phase I results. Proc Am Assoc Cancer Res 30:271Google Scholar
  5. Grau C, Overgaard J (1990) The influence of radiation dose on the magnitude and kinetics of reoxygenation in a C3H mammary carcinoma. Radiat Res 122:309–315Google Scholar
  6. Gruber M, Prados M, Russell C, Hochberg F, Cook P, Weissman D, Evans R, Burton G, Allen D, Brannon R (1990) Phase I/II study of Fluosol/O2 in combination with BCNU in malignant glioma. Proc Am Assoc Cancer Res 31:190Google Scholar
  7. Howes AE, Page A, Fowler JF (1972) The effects of single and fractionated doses of x-rays on the effective proportion of hypoxic cells in C3H mouse mammary tumors. Br J Radiol 45:250–256Google Scholar
  8. Jain RK (1988) Determinants of tumor blood flow: a review. Cancer Res 48:2641–2658Google Scholar
  9. Kallman RF (1988) Reoxygenation and repopulation in irradiated tumors. Front Radiat Ther Oncol 22:30–49Google Scholar
  10. Kallman RF, Jardine LJ, Johnson CW (1970) Effects of different schedules of dose fractionation on the oxygenation status of a transplantable mouse sarcoma. J Natl Cancer Inst 44:369–377Google Scholar
  11. Lustig R, McIntosh-Lowe N, Rose C, Haas J, Krasnow S, Spaulding M, Prosnitz L (1989) Phase I/II study of Fluosol-DA and 100% oxygen as an adjuvant to radiation in the treatment of advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 16:1587–1593Google Scholar
  12. Lustig R, Lowe N, Prosnitz L, Spaulding M, Cohen M, Stitt J, Brannen R (1990) Phase I/II study of Fluosol-DA and 100% oxygen breathing as an adjuvant to radiation in the treatment of unresectable non small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 19:97–102Google Scholar
  13. Meyers F, Alberts D, Spaulding M, Garewal H, Flam M, Allen D (1989) Phase I/II study of Fluosol/oxygen in combination with weekly 5-fluorouracil (5FU) in metastatic colorectal carcinoma. Proc Am Assoc Cancer Res 30:256Google Scholar
  14. Riess JG (1984) Reassessment of criteria for the selection of perfluorochemicals for second-generation blood substitutes: analysis of structure/property relationships. Artif Organs 8:44–56Google Scholar
  15. Rose C, Lustig R, McIntosh N, Teicher BA (1986) A clinical trial of Fluosol-DA in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 12:1325–1327Google Scholar
  16. Sevick EM, Jain RK (1989) Geometric resistance to blood flow in solid tumors perfusedex vivo: effects of tumor size and perfusion pressure. Cancer Res 49:3513–3519Google Scholar
  17. Teicher BA, Holden SA (1987) A survey of the effect of adding Fluosol-DA 20%/O2 to treatment with various chemotherapeutic agents. Cancer Treat Rep 71:173–177Google Scholar
  18. Teicher BA, Holden SA, Rose CM (1985) Differential enhancement of melphalan cytoxicity in tumor and normal tissue by Fluosol-DA and oxygen breathing. Int J Cancer 36:585–589Google Scholar
  19. Teicher BA, Crawford JM, Holden SA, Cathcart KNS (1987) Effects of various oxygenation conditions on the enhancement by Fluosol-DA of melphalan antitumor activity. Cancer Res 47:5036–5041Google Scholar
  20. Teicher BA, Holden SA, Jacobs JL (1987) Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity. Cancer Res 47:513–518Google Scholar
  21. Teicher BA, Herman TS, Holden SA, Cathcart KNS (1988a) The effect of Fluosol-DA and oxygenation status on the activity of cyclo phosphamidein vivo. Cancer Chemother Pharmacol 21:286–291Google Scholar
  22. Teicher BA, Herman TS, Rose CM (1988b) Effect of Fluosol-DA on the response of intracranial 9L tumors to x-rays and BCNU. Int J Radiat Oncol Biol Phys 15:1187–1192Google Scholar
  23. Teicher BA, Holden SA, Al-Achi A, Herman TS (1990) Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulationsin vivo in FSallC murine fibrosarcoma. Cancer Res 50:3339–3344Google Scholar
  24. Teicher BA, Holden SA, Rose CM (1986) Effect of Fluosol-DA/O2 on tumor cell and bone marrow cytotoxicity of nitrosoureas in mice bearing FSall fibrosarcoma. Int J Cancer 38:285–288Google Scholar
  25. Teicher BA, Lazo JS, Sartorelli AC (1981) Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 41:73–81Google Scholar
  26. Teicher BA, McIntosh-Lowe NL, Rose CM (1988) Effect of various oxygenation conditions and Fluosol-DA on cancer chemotherapeutic agents. Biomater Artif Cells Immunobiol Biotechnol 16:533–546Google Scholar
  27. Teicher BA, Waxman DJ, Holden SA, Wang Y, Clarke L, Alvarez Sotomayor E, Jones SM, Frei E (1989) Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity ofN,N′,N′-triethylenethiophosphoramide. Cancer Res 49:4996–5001Google Scholar
  28. Thomlinson RH (1968) Changes of oxygenation in relation to irradiation. Front Radiat Ther Oncol 3:109–121Google Scholar
  29. Van Putten LM (1968) Tumor reoxygenation during fractionated radiotherapy: studies with transplantable mouse osteosarcoma. Eur J Cancer 4:173–182Google Scholar
  30. Van Putten LM, Kallman RF (1982) Oxygenation status of a transplantable tumor during fractionated radiation therapy. J Natl Cancer Inst 40:441–451Google Scholar
  31. Vaupel PW (1993) Oxygenation of solid tumors. In: Teicher B (ed) Drug resistance in oncology. Dekker, New York, pp 53–87Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • Beverly A. Teicher
    • 1
  • Enrique Alvarez Sotomayor
    • 1
  • Norman P. Dupuis
    • 1
  • Tetsuya Kusumoto
    • 1
  • Krishna Menon
    • 1
  1. 1.Dana-Farber Cancer Institute and Joint Center for Radiation TherapyBostonUSA

Personalised recommendations